Our study indicates that p35 deregulation through miR-26a plays an important role in DLBCL growth and, following further studies in patient samples, it may be considered as a novel prognostic marker and a potential therapeutic target for DLBCL. This evidence concerns the gene CDK5R1 and diffuse large B-cell lymphoma.